|
1
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: Epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al; SHARP Investigators Study Group. Sorafenib in advanced
hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Huynh H: Tyrosine kinase inhibitors to
treat liver cancer. Expert Opin Emerg Drugs. 15:13–26. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Olsen SK, Brown RS and Siegel AB:
Hepatocellular carcinoma: Review of current treatment with a focus
on targeted molecular therapies. Therap Adv Gastroenterol. 3:55–66.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Whittaker S, Marais R and Zhu AX: The role
of signaling pathways in the development and treatment of
hepatocellular carcinoma. Oncogene. 29:4989–5005. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hsu C, Yang TS, Huo TI, Hsieh RK, Yu CW,
Hwang WS, Hsieh TY, Huang WT, Chao Y, Meng R, et al: Vandetanib in
patients with inoperable hepatocellular carcinoma: A phase II,
randomized, double-blind, placebo-controlled study. J Hepatol.
56:1097–1103. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lin AY, Fisher GA, So S, Tang C and Levitt
L: Phase II study of imatinib in unresectable hepatocellular
carcinoma. Am J Clin Oncol. 31:84–88. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Faivre S, Raymond E, Boucher E, Douillard
J, Lim HY, Kim JS, Zappa M, Lanzalone S, Lin X, Deprimo S, et al:
Safety and efficacy of sunitinib in patients with advanced
hepatocellular carcinoma: An open-label, multicentre, phase II
study. Lancet Oncol. 10:794–800. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Linger RM, Keating AK, Earp HS and Graham
DK: TAM receptor tyrosine kinases: Biologic functions, signaling,
and potential therapeutic targeting in human cancer. Adv Cancer
Res. 100:35–83. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang YX, Knyazev PG, Cheburkin YV, Sharma
K, Knyazev YP, Orfi L, Szabadkai I, Daub H, Kéri G and Ullrich A:
AXL is a potential target for therapeutic intervention in breast
cancer progression. Cancer Res. 68:1905–1915. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Taylor IC, Roy S, Yaswen P, Stampfer MR
and Varmus HE: Mouse mammary tumors express elevated levels of RNA
encoding the murine homology of SKY, a putative receptor tyrosine
kinase. J Biol Chem. 270:6872–6880. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
De Vos J, Couderc G, Tarte K, Jourdan M,
Requirand G, Delteil MC, Rossi JF, Mechti N and Klein B:
Identifying inter-cellular signaling genes expressed in malignant
plasma cells by using complementary DNA arrays. Blood. 98:771–780.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wimmel A, Rohner I, Ramaswamy A, Heidtmann
HH, Seitz R, Kraus M and Schuermann M: Synthesis and secretion of
the anticoagulant protein S and coexpression of the Tyro3 receptor
in human lung carcinoma cells. Cancer. 86:43–49. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ho HK, Chua BT, Wong W, Lim KS, Teo V, Ong
HT, Chen X, Zhang W, Hui KM, Go ML, et al: Benzylidene-indolinones
are effective as multi-targeted kinase inhibitor therapeutics
against hepatocellular carcinoma. Mol Oncol. 8:1266–1277. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ho HK, Pok S, Streit S, Ruhe JE, Hart S,
Lim KS, Loo HL, Aung MO, Lim SG and Ullrich A: Fibroblast growth
factor receptor 4 regulates proliferation, anti-apoptosis and
alpha-feto-protein secretion during hepatocellular carcinoma
progression and represents a potential target for therapeutic
intervention. J Hepatol. 50:118–127. 2009. View Article : Google Scholar
|
|
16
|
Taylor IC, Roy S and Varmus HE:
Overexpression of the Sky receptor tyrosine kinase at the cell
surface or in the cytoplasm results in ligand-independent
activation. Oncogene. 11:2619–2626. 1995.PubMed/NCBI
|
|
17
|
Abelev GI and Eraiser TL: Cellular aspects
of alpha-fetoprotein reexpression in tumors. Semin Cancer Biol.
9:95–107. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vibert E, Azoulay D, Hoti E, Iacopinelli
S, Samuel D, Salloum C, Lemoine A, Bismuth H, Castaing D and Adam
R: Progression of alphafetoprotein before liver transplantation for
hepatocellular carcinoma in cirrhotic patients: a critical factor.
Am J Transplant. 10:129–137. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Katagiri M, Hakeda Y, Chikazu D, Ogasawara
T, Takato T, Kumegawa M, Nakamura K and Kawaguchi H: Mechanism of
stimulation of osteoclastic bone resorption through Gas6/Tyro 3, a
receptor tyrosine kinase signaling, in mouse osteoclasts. J Biol
Chem. 276:7376–7382. 2001. View Article : Google Scholar
|
|
20
|
Toshima J, Ohashi K, Iwashita S and Mizuno
K: Autophosphorylation activity and association with Src family
kinase of Sky receptor tyrosine kinase. Biochem Biophys Res Commun.
209:656–663. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lan Z, Wu H, Li W, Wu S, Lu L, Xu M and
Dai W: Transforming activity of receptor tyrosine kinase tyro3 is
mediated, at least in part, by the PI3 kinase-signaling pathway.
Blood. 95:633–638. 2000.PubMed/NCBI
|
|
22
|
Zhu S, Wurdak H, Wang Y, Galkin A, Tao H,
Li J, Lyssiotis CA, Yan F, Tu BP, Miraglia L, et al: A genomic
screen identifies TYRO3 as a MITF regulator in melanoma. Proc Natl
Acad Sci USA. 106:17025–17030. 2009. View Article : Google Scholar : PubMed/NCBI
|
